305 related articles for article (PubMed ID: 23057994)
1. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
[TBL] [Abstract][Full Text] [Related]
2. Long-term cardiac effects of treatment for childhood leukemia.
Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
[TBL] [Abstract][Full Text] [Related]
3. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors.
Hu H; Zhang W; Huang D; Yang Q; Li J; Gao Y
Pediatr Hematol Oncol; 2018 Mar; 35(2):111-120. PubMed ID: 29648903
[TBL] [Abstract][Full Text] [Related]
5. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
[TBL] [Abstract][Full Text] [Related]
7. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
8. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
9. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
11. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
[TBL] [Abstract][Full Text] [Related]
12. Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines.
Pourier MS; Mavinkurve-Groothuis AMC; Dull MM; Weijers G; Loonen J; Bellersen L; de Korte CL; Kapusta L
Am J Cardiol; 2020 Jul; 127():163-168. PubMed ID: 32444028
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.
Lipshultz SE; Landy DC; Lopez-Mitnik G; Lipsitz SR; Hinkle AS; Constine LS; French CA; Rovitelli AM; Proukou C; Adams MJ; Miller TL
J Clin Oncol; 2012 Apr; 30(10):1050-7. PubMed ID: 22393080
[TBL] [Abstract][Full Text] [Related]
14. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
15. Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.
Ylänen K; Poutanen T; Savukoski T; Eerola A; Vettenranta K
Acta Paediatr; 2015 Mar; 104(3):313-9. PubMed ID: 25393922
[TBL] [Abstract][Full Text] [Related]
16. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
[TBL] [Abstract][Full Text] [Related]
17. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
18. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.
Roziakova L; Bojtarova E; Mistrik M; Dubrava J; Gergel J; Lenkova N; Mladosievicova B
J Exp Clin Cancer Res; 2012 Feb; 31(1):13. PubMed ID: 22321767
[TBL] [Abstract][Full Text] [Related]
19. Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy.
Ehrhardt MJ; Liu Q; Mulrooney DA; Rhea IB; Dixon SB; Lucas JT; Sapkota Y; Shelton K; Ness KK; Srivastava DK; McDonald A; Robison LL; Hudson MM; Yasui Y; Armstrong GT
J Clin Oncol; 2024 Apr; 42(11):1265-1277. PubMed ID: 38207238
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
